PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUGS IN PATIENTS WITH RENAL DYSFUNCTION

  • K. Zakon
  • V. Dudarenko
  • M. Kolesnyk
Keywords: pharmacokinetics, pharmacodynamics, chronic kidney disease, acute kidney injury, renal replacement therapy, drugs

Abstract

This review is dedicated to drugs` pharmacokinetics and pharmakodynamcs in patients with renal dysfunction.

Downloads

Download data is not yet available.

References

Bartal C. Pharmacokinetic dosing of aminoglycosides: a controlled trial / Bartal C., Danon A., Schlaeffer F., Reisenberg K., Alkan M., Smoliakov R., et al. // Am. J. Med. – 2003. – V. 114. – Р. 194–8.

Benet L.Z. Transporter-enzyme interactions: implications for predicting drug- drug interactions from in vitro data / Benet L.Z., Cummins C.L., Wu C.Y. // Curr. Drug. Metab. – 2003. – V. 4. – Р. 393–398.

Bradley A. Boucher Pharmacokinetic Changes in Critical Illness / Bradley A. Boucher, PharmD, BCPSa,b,T, G. Christopher Wood, PharmD, BCPSa, Joseph M. Swanson, PharmD, BCPS // Crit. Care Clin. – 2006. – V. 22. – Р. 255– 271.

Bricker N.S. The pathologic physiology of chronic Bright’s Disease: an exposition of the “intact nephron hypothesis” / Bricker N.S., Morrin P.A.F., Kime S.W. Jr. // J. Am. Soc. Nephrol. – 1997. – V. 8. Р. 1470–1476.

Brophy D.F. Use of enoxaparin in patients with chronic kidney disease: safety considerations / Brophy D.F., Sica D.A. // Drug Saf. – 2007. – V. 30. – Р. 991– 994.

Dale O. Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery / Dale O., Thoner J., Nilsen T., Tveita T., Borchgrevink P.C., Klepstad P. // Eur. J. Clin. Pharmacol. – 2007. – V. 63. – Р. 837–842.

Dowling T.C. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease / Dowling T.C., Briglia A.E., Fink J.C., Hanes D.S., Light P.D., Stackiewicz L., Karyekar C.S., Eddington N.D., Weir M.R., Henrich W.L. // Clin. Pharmacol. Ther. – 2003. – V. 73. – Р. 427–434

Dreisbach A.W. Cytochrome P4502C9 activity in end-stage renal disease / Dreisbach A.W., Japa S., Gebrekal A.B., Mowry S.E., Lertora J.J.L., Kamath B.L., Rettie A.E. // Clin. Pharmacol. Ther. – 2003. – V. 73. – Р. 475–477.

Francesco Scaglione Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens / Francesco Scaglione, Luca Paraboni // International Journal of Antimicrobial Agents. – 2008. – V. 32. – Р.294–301.

Frassetto L.A. Effects of uptake and efflux transporter inhibition on erythromycin breath test results / Frassetto L.A., Poon S., Tsourounis C., Valera C., Benet L.Z. // Clin. Pharmacol. Ther. – 2007. – V. 81. – Р. 828–832.

Frye R.F. Liver disease Selectivey modulates cytochrome P450- mediated metabolism drugs in liver / Frye R.F. et al. // Clin. Pharmacol. Ther. – 2006. – V. 80. – Р. 235–245.

Golper T.A. Drug removal during continuous renal replacement therapy / Golper T.A. // In Rose BD (ed): Nephrology Up-To-Date. –1994. – V. 2. (13).

Hernandez G. Gut mucosal atrophy after a short enteral fasting period in critically ill patients / Hernandez G., Velasco N., Wainstein C., et al. // J. Crit. Care. – 1999. – V. 14(2). – Р. 73 – 7.

Heyland D.K. Cisapride improves gastric emptying in mechanically ventilated, critically ill patients. A randomized, double-blind trial / Heyland D.K., Tougas G., Cook D.J., et al. // Am. J. Respir. Crit. Care Med. – 1996. – V. 154(6 Pt 1). – Р.1678–83.

Hiraoka H. Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain / Hiraoka H., Yamamoto K., Miyoshi S., Morita T., Nakamura K., Kadoi Y., Kunimoto F., Horiuchi R. // Br. J. Clin. Pharmacol. – 2005. – V. 60. – Р. 176–182.

Ho R.H. Transporters and drug therapy: implications for drug disposition and disease / Ho R.H., Kim R.B. // Clin. Pharmacol. Ther. – 2005. – V. 78. – Р. 260–277.

How P.P. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin / How P.P., Fischer J.H., Arruda J.A. et al. // Clin. J. Am. Soc. Nephrol. – 2007. – V. 2. – Р. 1235–1240.

Hulot J.S. Effect of renal failure on the pharmacokinetics of enoxaparin and consequences on dose adjustment / Hulot J.S., Vantelon C., Urien S., Bouzamondo A., Mahe I., Ankri A., Montalescot G., Lechat P. // Ther. Drug Monit. – 2004. – V. 26. – Р. 305–310.

Introduction to pharmacokinetics and pharmacodynamics: the quantitative basis of drug therapy / Tozer T.N., Rowland M. // Lippincott Williams & Williams, Philadelphia, – 2006. – pp. 97–100.

Jacobi J. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult / Jacobi J., Fraser G.L., Coursin D.B., et al. // Crit. Care Med. – 2002. – V. 30(1). – Р. 119– 41.

Kays M.B. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin / Kays M.B., Overholser B.R., Mueller B.A. et al. // Am. J. Kidney Dis. – 2003. – V. 42. – Р. 1253–1259.

Lam YWF. Principles of drug administration in renal insufficiency / Lam Y.W.F., Banerji S., Hatfield C., Talbert R.L. // Clin. Pharmacokinet. – 1997.– V. 32. – Р. 30–57.

Lee W. Transporters and renal elimination / Lee W., Kim B // Annu. Rev. Pharmacol. Toxicol. – 2004. – V. 44. – Р. 137–166.

Maher J.F. Pharmacokinetics in patients with renal failure / Maher J.F.// Clin. Nephrol. – 1984. – V. 21. – Р. 39–46.

Maher J.F. Principles of dialysis and dialysis of drugs / Maher J.F.// Am. J. Med. – 1977. – V. 62. – Р.475–81.

Naud J. Down-regulation of intestinal drug transporters in chronic renal failure in rats / Naud J., Michaud J., Boisvert C., Desbiens K., Leblod F.A., Mitchell A., Jones C., Bonnardeaux A., Pichette V. // J. Pharmacol. Exp. Ther. – 2007. – V. 320. – Р. 978–985.

Naud J. Effects of chronic renal failure on liver drug transporters / Naud J., Michaud J., Leblond F.A., Lefrancois S., Bonnardeaux A., Pichette V. // Drug Metab. Disp. – 2008. – V. 36. – Р. 124–128.

Piraino B. Peritoneal dialysis-related infections recommendations: 2005 update. / Piraino B., Bailie GR, Bernardini J, et al. // Peritoneal Dialysis International – 2005. – V.25. – Р. 107–131.

Penson R.T. Morphine analgesia in cancer pain: role of the glucuronides / Penson R.T., Joel S.P., Gloyne A., Clark S., Slevin M.L. // J. Opioid Manag. – 2005. – V. 1. – Р. 83–90.

Pinder M. Pharmacological principles of antibiotic prescription in the critically ill / Pinder M., Bellomo R., Lipman J. // Anaesth Intensive Care. – 2002. – V. 30. – Р. 134–44.

Priglinger U. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? / Priglinger U., Delle Karth G., Geppert A., et al. // Crit. Care Med. – 2003. – V. 31(5). – Р. 1405– 9.

Roger K. Pharmacokinetics and dosage adjustment in patients with renal dysfunction / Roger K. Verbeeck & Flora T. Musuamba // Eur J Clin Pharmacol. – 2009. – V. 65. – Р. 757–773.

Sampol E. Plasma, urine and skin pharmacokinetics of cefepime in burns patients / Sampol E., Jacquet A., Viggiano M., Bernini V., Manelli J.C., Lacarelle B., et al. // J. Antimicrob. Chemother. – 2000. – V. 46. – Р. 315–7.

Tett S.E. Principles and clinical application of assessing alterations in renal elimination pathways / Tett S.E., Kirkpatrick C.M.J., Gross A.S., McLachlan A.J. // Clin. Pharmacokinet. – 2003. – V. 42. – Р. 1193–1211.

Verbeeck R.K. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction / Verbeeck R.K. // Eur. J. Clin. Pharmacol. – 2008. – V. 64. – Р. 1147–1161.


Abstract views: 764
PDF Downloads: 220
Published
2017-12-12
How to Cite
Zakon, K., Dudarenko, V., & Kolesnyk, M. (2017). PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUGS IN PATIENTS WITH RENAL DYSFUNCTION. Ukrainian Journal of Nephrology and Dialysis, (3(39), 51-57. https://doi.org/10.31450/ukrjnd.3(39).2013.08

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>